To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 3
This profile is validated by 3 label.

Company

Synthebio

Synthebio_logo
18
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Paris, Île-de-France, France

Send a message

  • 3

    employees

English

English

French

Synthebio
English

English

French

Accelerator Application

The localized adiposity is a disease recognized by the WHO that affects 1.4 B people (3.3 B in 2030). Synthebio has developed, with CNRS experts, the Convergent Ultrasound technology that radically eliminates localized body fat excess (adiposity) and provides results never achieved until now: up to 5 cm. waistline reduction after one 20-minutes session. Synthebio has developed a non-invasive medical device, the Slimiser that also uses digital management of...

See more

Accelerator Application

The localized adiposity is a disease recognized by the WHO that affects 1.4 B people (3.3 B in 2030). Synthebio has developed, with CNRS experts, the Convergent Ultrasound technology that radically eliminates localized body fat excess (adiposity) and provides results never achieved until now: up to 5 cm. waistline reduction after one 20-minutes session. Synthebio has developed a non-invasive medical device, the Slimiser that also uses digital management of ultrasound, shape recognition based on based on IA, augmented reality guidance of the physician.
This medical device is being CE marked and should reach the market this year.
Dr. Kleinsinger runs Synthebio. He created and managed Optis - Eyegate Pharmaceuticals for 8 years, that went public and is listed on Nasdaq.
The body contouring market is huge (4 B€, 27 B€ in 2030), international and rapidly growing (19% per year). The goal is to develop a midsize company that could become a leader in the booming market of esthetic medicine.

  • 1

    Like

Our latest news

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
116 Entities
Adhérent Medicen
22 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1036 Members